

DAFTAR PUSTAKA

1. Lunn MR, Wang CH. Spinal muscular atrophy. *Lancet*. 2008;371(2):2120–33.
2. Verhaart IEC, Robertson A, Wilson IJ, Aartsma-Rus A, Cameron S, Jones CC, et al. Prevalence, incidence and carrier frequency of 5q-linked spinal muscular atrophy - A literature review. *Orphanet J Rare Dis*. 2017;12(1):1–15.
3. Baioni MTC, Ambiel CR. Spinal muscular atrophy: Diagnosis, treatment and future prospects. *J Pediatr (Rio J)*. 2010;86(4):261–70.
4. Baioni MT., Ambiel CR. Spinal Muscular Atrophy: diagnosis, treatment and future prospects. *J Pediatr (Rio J)*. 2010;86(4):261–70.
5. Monani UR. Spinal muscular atrophy: A deficiency in a ubiquitous protein; a motor neuron-specific disease. *Neuron*. 2005;48(6):885–95.
6. Akutsu T, Nishio H, Sumino K, Takeshima Y, Tsuneishi S, Wada H, et al. Molecular genetics of spinal muscular atrophy: Contribution of the NAIP gene to clinical severity. *Kobe J Med Sci*. 2002;48(1–2):25–31.
7. Prior TW. Spinal muscular atrophy Diagnostics. *J Child Neurol*. 2007;952–6.
8. Goodman R, Content I. Strengths and Difficulties Questionnaire (SDQ). *Ment Heal Suicide Prev Branch, Dep Heal Ageing [Internet]*. 2002;1–25. Available from: <http://www.sdqinfo.com>.
9. Tsai LK. Therapy development for spinal muscular atrophy in SMN independent targets. *Neural Plast*. 2012;2012.
10. Lewelt A, Newcomb TM, Swoboda KJ. New therapeutic approaches to spinal muscular atrophy. *Curr Neurol Neurosci Rep*. 2012;12(1):42–53.
11. Wadman RI, van der Pol WL, Bosboom WMJ, Asselman FL, van den Berg LH, Iannaccone ST, et al. Drug treatment for spinal muscular atrophy types II and III. *Cochrane Database Syst Rev*. 2020;2020(1).
12. Tikoo A, Kothari MK, Shah K, Nene A. Current Concepts - Congenital Scoliosis. *Open Orthop J*. 2017;11(1):337–45.
13. Arnold WD, Kassar D, Kissel JT. Spinal muscular atrophy: Diagnosis and management in a new therapeutic era. *Muscle and Nerve*. 2015;51(2):157–67.
14. Ge X, Bai J, Lu Y, Qu Y, Song F. The natural history of infant spinal muscular atrophy in China: A study of 237 patients. *J Child Neurol*. 2012;27(4):471–7.

15. Sproule DM, Hasnain R, Koenigsberger D, Montgomery M, De Vivo DC, Kaufmann P. Age at disease onset predicts likelihood and rapidity of growth failure among infants and young children with spinal muscular atrophy types 1 and 2. *J Child Neurol*. 2012;27(7):845–51.
16. Nurputra DK, Lai PS, Harahap NIF, Morikawa S, Yamamoto T, Nishimura N, et al. Spinal muscular atrophy: From gene discovery to clinical trials. *Ann Hum Genet*. 2013;77(5):435–63.
17. Darbar IA, Plaggert PG, Resende MBD, Zanoteli E, Reed UC. Evaluation of muscle strength and motor abilities in children with type II and III spinal muscle atrophy treated with valproic acid. *BMC Neurol* [Internet]. 2011;11(1):36. Available from: <http://www.biomedcentral.com/1471-2377/11/36>
18. Pedoman Teknis Penilaian Rumah Sehat. Dep Kesehat Republik Indones. 2002;53(9):1689–99.